(Q30359348)

20 June 2017

The utility of ISCOMATRIX adjuvant for dose reduction of antigen for vaccines requiring antibody responses. (English)

1 reference

20 June 2017

1 reference

Jeff Boyle

1

1 reference

20 June 2017

Donna Eastman

2

1 reference

20 June 2017

Christine Millar

3

1 reference

20 June 2017

Sarina Camuglia

4

1 reference

20 June 2017

John Cox

5

1 reference

20 June 2017

Martin Pearse

6

1 reference

20 June 2017

Jeremy Good

7

1 reference

20 June 2017

Debbie Drane

8

1 reference

20 June 2017

language of work or name

English

0 references

publication date

29 December 2006

1 reference

20 June 2017

1 reference

20 June 2017

25

1 reference

20 June 2017

14

1 reference

20 June 2017

2541-2544

1 reference

Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans

20 June 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.018

Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.018

Iscoms Containing PurifiedQuillajaSaponins Upregulate both Th1-like and Th2-like Immune Responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.018

Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.018

Immunomodulation by iscoms, immune stimulating complexes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.018

Immune responses to ISCOM formulations in animal and primate models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.018

Induction of lymphocyte recruitment in the absence of a detectable immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.018

Interactions between Immune-Stimulating Complexes (ISCOMs) and Peritoneal Mononuclear Leucocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.018

NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ t-cell-mediated immunity and protection against NY-ESO-1+ tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.018

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.018

Augmentation of human influenza A virus-specific cytotoxic T lymphocyte memory by influenza vaccine and adjuvanted carriers (ISCOMS).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.018

Studies on experimental adjuvanted influenza vaccines: comparison of immune stimulating complexes (Iscoms) and oil-in-water vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.018

Immunopotentiation of humoral and cellular responses to inactivated influenza vaccines by two different adjuvants with potential for human use

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.018

10.1016/J.VACCINE.2006.12.018

7 January 2021

Identifiers

DOI

1 reference

20 June 2017

1 reference